Saruparib

Saruparib (AZD5305) is AstraZeneca's next-generation PARP inhibitor that selectively hits PARP1 - instead of both PARP1 and PARP2 like the four approved agents (olaparib, talazoparib, niraparib, rucaparib) - and is also a potent PARP1 trapper. The design choice should let it combine with other drugs without the bone-marrow toxicity that limits olaparib. The Phase 3 EvoPAR-B01 trial (NCT06380751) pairs saruparib with camizestrant against physician's choice CDK4/6 inhibitor plus endocrine therapy in first-line HR+/HER2- breast cancer patients carrying BRCA1, BRCA2, or PALB2 mutations. The bet: cleaner toxicity from PARP1 selectivity lets AZ build PARP-based combinations that older drugs in the class could not sustain - and critically, do so before Lynparza (olaparib) loses exclusivity.

Saruparib is a novel compound, never approved anywhere in the world. AstraZeneca has it running in three Phase 3 trials simultaneously: this HR+/HER2- breast cancer trial (NCT06380751, n=500) in BRCA1/BRCA2/PALB2 carriers; EvoPAR-Prostate01 (NCT06120491, n=1800) in metastatic castration-sensitive prostate cancer; and a high-risk localized BRCA-mutant prostate trial (NCT06952803, n=700) [1][2][3]. There is also an ongoing Phase 1/2 monotherapy and combination program (PETRA, NCT04644068) and an earlier-line program with AZD9750. No FDA breakthrough therapy or fast track designation has been publicly disclosed for the breast cancer indication that I can verify. The drug carries no approvals it could use as accelerated pathways. Why three Phase 3 trials at once: Lynparza (olaparib) loss-of-exclusivity is the commercial driver. Lynparza's primary US patent protection expires around September 2027, with biosimilar entry expected 2027-2029 across geographies [9]. AZ generated ~$3.7B in Lynparza revenue in 2024 [4], and the franchise needs a successor in market before LOE bites. Saruparib's plausible primary readouts (2027-2028) map almost exactly to that gap - that's why parallel execution, not sequential, is the strategy. Timeline is the soft spot. The breast trial uses progression-free survival as primary endpoint with n=500 in a biomarker-selected first-line population. PFS events accumulate slowly in HR+/HER2- BRCA-mutant breast cancer because median PFS on CDK4/6i + ET runs 25-30 months. Realistic primary readout is 2028, with interim safety data potentially at ESMO 2026 or 2027. The two prostate Phase 3s are larger and earlier in enrollment; those readouts will likely come first and inform whether AZ accelerates the breast program or pulls back. The commercial framing matters: AstraZeneca generated $54.1B in total revenue in FY2024 [10] and Lynparza alone contributed roughly $3.7B [4]. Saruparib is positioned as olaparib's combination-friendly successor.

PARP enzymes are protein machines that patch single-strand breaks in DNA, the small everyday damage that happens during normal cell life. Block PARP and those single-strand breaks turn into double-strand breaks when DNA is being copied during cell division. Cells with intact homologous recombination repair (the BRCA1, BRCA2, and PALB2 system) fix double-strand breaks accurately. Cells where those genes are mutated cannot, and they die. This is synthetic lethality: two harmless genetic changes become deadly when combined. Two mechanisms drive PARP inhibitor cytotoxicity, not one. The first is catalytic blockade - stopping the enzyme from doing its repair work. The second, and arguably more important, is PARP trapping: the inhibitor locks PARP onto the broken DNA, creating a stuck protein-DNA complex that physically blocks the replication machinery. Trapped PARP-DNA complexes are far more cytotoxic than simple enzyme inhibition. Trapping potency does not perfectly correlate with selectivity, so a drug can be highly selective and still be a strong trapper - saruparib is engineered to be both. The first-generation PARP inhibitors - olaparib (Lynparza), talazoparib (Talzenna), niraparib (Zejula), rucaparib (Rubraca) - all hit both PARP1 and PARP2 enzymes. PARP1 drives the cancer-killing effect. PARP2 inhibition contributes to bone marrow suppression: anemia, thrombocytopenia, neutropenia. That toxicity kept first-gen PARP combinations narrow. Saruparib is roughly 500-fold more selective for PARP1 over PARP2 and is a potent PARP1 trapper. Phase 1 PETRA data published in Cancer Discovery 2022 showed substantially cleaner hematologic profile at doses producing strong PARP1 trapping [5]. The selectivity-plus-trapping combination is the differentiation thesis: open the door to combinations (PARP + endocrine therapy, PARP + ADT [androgen deprivation therapy], PARP + radiation) that earlier PARPs could not sustain because of cytopenias, while preserving the trapping-driven kill mechanism. The genetic case for synthetic lethality is among the strongest in oncology. Olaparib hit OlympiAD's primary endpoint in BRCA-mutant metastatic breast cancer with HR 0.58 [7], succeeded in OlympiA adjuvant breast, in PROfound prostate, in SOLO ovarian, in POLO pancreatic. The mechanism delivers when patients are correctly selected. Saruparib's bet is not whether PARP inhibition works in BRCA-mutant cancers; it is whether cleaner toxicity creates a meaningfully better drug in combinations.

The trial is Phase 3, NCT06380751, sponsored by AstraZeneca, currently recruiting toward n=500 [1]. Population: first-line metastatic HR+/HER2- (standard HER2-negative by pathology testing) breast cancer with germline or somatic BRCA1, BRCA2, or PALB2 mutations. The biomarker selection is tight - all three genes converge on homologous recombination, the exact pathway PARP inhibition exploits. Two experimental arms test saruparib + camizestrant against the active comparator: physician's choice CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) plus endocrine therapy. Camizestrant is AstraZeneca's next-generation oral selective estrogen receptor degrader (SERD) and is itself unapproved - it remains in Phase 3 (SERENA-4 first-line, SERENA-6 ESR1-mutant switch). SERENA-6 reported in 2025 a 56% PFS risk reduction (HR ~0.44) in ESR1-mutant patients switched to camizestrant [11], strengthening the case for camizestrant as a partner asset, but its regulatory status is still pending. So AZ is testing two of its own pipeline assets together - strategically sensible and analytically clean if both signals separate, but it stacks two unapproved-asset risks on one trial. Primary endpoint is progression-free survival, the right endpoint for first-line metastatic disease and what regulators have accepted across the CDK4/6i and PARP approval cohort. The design concern: the comparator is strong. CDK4/6i + AI delivered roughly 25-30 month median PFS across PALOMA-2, MONALEESA-2, and MONARCH-3. To win, saruparib + camizestrant has to clear that bar specifically in BRCA-mutant patients - a population where PARP biology should give an edge but where CDK4/6i benefit also persists. Hazard ratio target is likely around 0.65 to power detection at n=500. Recruitment is biomarker-restricted, slowing enrollment and pushing readout toward 2028. Addressable population: roughly 70% of metastatic breast cancer is HR+/HER2-. US incidence of metastatic HR+/HER2- breast cancer is on the order of 30-40K patients/year. Germline BRCA1/BRCA2 carriers are 5-7% of HR+/HER2- mBC; PALB2 adds another 1-2%; somatic mutations add a smaller increment. That implies roughly 2,000-4,000 first-line eligible US patients/year - a defined biomarker niche, not a mass-market indication, but with high per-patient revenue potential.

Our model gives this drug a 34% chance of eventually being approved. Drugs at Phase 3 in this area are approved about 48% of the time, and ten facts about this trial and sponsor push the estimate below that starting point. The main factors helping it are the trial's open-label design, more secondary endpoints than usual, and the sponsor's strong track record of getting drugs approved. What pulls the number down are weaker results from earlier phases of testing.

Efficacy: the comparator arm is genuinely strong. First-line CDK4/6i + ET delivers about 28 months median PFS across approved drugs. Saruparib + camizestrant has to clear that in BRCA-mutant patients meaningfully - probably HR ≤ 0.65 to drive registration and adoption. If PARP-endocrine synergy in BRCA carriers is smaller than the OlympiAD-class data suggests, the trial reads flat. Safety: PARP1 selectivity is the entire premise, and Phase 1 PETRA showed cleaner hematologic profile at exposure-equivalent doses [5]. But Phase 1 is short-duration. Long-duration combination with camizestrant, which itself has bradycardia and visual disturbance signals, is untested territory. MDS/AML - myelodysplastic syndrome and acute myeloid leukemia, two serious bone-marrow cancers - is the long-tail PARP risk that takes years to surface. Because PARP inhibitors damage hematopoietic stem cells over time, prolonged exposure raises the risk of these secondary cancers and would constrain duration of therapy if rates rise above background. PARP1 selectivity may help here, but the data is not yet long enough to confirm. Execution: biomarker-selected enrollment slows trials. About 5-10% of HR+/HER2- breast cancer carries BRCA1, BRCA2, or PALB2 germline mutations; somatic mutations add modestly. Olaparib (OlympiA) and talazoparib (Talzenna) compete for the same patients in adjuvant and metastatic settings respectively. Recruitment delays into 2028 are realistic. Competitive landscape for next-gen PARP1-selective agents is also tightening - multiple developers (including AbbVie programs and PARP1-selective candidates from biotech entrants) are advancing similar profiles, and saruparib will not be alone in the category by readout. Class headwinds: in March 2024 the FDA withdrew several PARP inhibitor indications in late-line ovarian cancer (rucaparib, niraparib, and olaparib indications) following overall-survival concerns from confirmatory trials. GSK's Zejula (niraparib) saw its US ovarian indications materially narrowed. The PARP class is no longer a free pass on regulatory tolerance; survival data, not just PFS, is increasingly scrutinized. Commercial: even on a positive readout, payer pressure on combination oncology regimens is severe. Lynparza generated ~$3.7B globally in 2024 [4]; layering camizestrant on top of saruparib pushes per-patient cost higher. CDK4/6i + ET has entrenched first-line position, and rotating PARP to second-line is the established practice pattern in BRCA carriers. Overturning that requires not just statistical superiority but clinically convincing magnitude. AZ has the franchise scale to push the conversation, but it is not a slam dunk.

Worth watching. The Lynparza loss-of-exclusivity timeline (US patent ~Sept 2027, biosimilars 2027-2029 [9]) is the single most important commercial frame for saruparib - AstraZeneca is running three simultaneous Phase 3 saruparib programs because the franchise needs a successor in-market before olaparib's $3.7B [4] revenue stream erodes. Parallel execution is a deliberate response to a hard deadline, not over-investment. EvoPAR-Prostate01 in metastatic castration-sensitive prostate cancer (NCT06120491, n=1800) is the larger commercial prize, and that trial will likely read out before the breast study [2]. Specific signal to wait for: interim safety data from any saruparib combination Phase 3 showing PARP1 selectivity holds in long-duration dosing. If the breast or prostate trials run at full dose without grade 3+ cytopenias clustering at olaparib-class rates, conviction goes up; that is the moment the differentiation thesis becomes real rather than theoretical. If hematologic AEs re-emerge in long combination exposure, this becomes another PARP combination story rather than a category reset. Check back at ESMO 2026 for any interim updates from EvoPAR-Prostate01 or the breast trial. ASCO 2027 is the more likely window for substantive efficacy data. The breast PFS readout is plausibly 2028. The bigger investor frame: saruparib's commercial value depends on AZ stacking PARP1-selective inhibition into ADC (antibody-drug conjugate) combinations, ATR inhibitor pairings (ceralasertib is AZ's lead ATR inhibitor), and earlier-line settings - programs that exist in earlier development but are not yet key. That is the franchise multiplier, not this one trial. AstraZeneca's $54.1B 2024 revenue base [10] gives the firepower to run all of those programs simultaneously, and the 2027 Lynparza patent cliff creates the urgency to do so.